{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:57:06Z","timestamp":1793048226356,"version":"4.5.0"},"reference-count":203,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Castration-resistant prostate cancer (CRPC) represents an advanced stage of prostate cancer progression. Although the combination of androgen deprivation therapy (ADT) with chemotherapy and first generation hormone therapy is initially effective, patients ultimately develop resistance. In recent years, breakthroughs in targeted therapies and immunotherapies, along with the emergence of novel combination strategies, have provided new hope for patients with CRPC. This article systematically reviews the latest advancements in targeted and immunotherapeutic approaches for CRPC, integrating clinical data and mechanistic studies to analyze the efficacy and challenges of novel agents (e.g., second-generation AR inhibitors, PARP inhibitors, PSMA-targeted therapies) and combination regimens. It also provides insights for exploring future optimization directions.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1668188","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:04Z","timestamp":1761111124000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted and immunotherapeutic strategies for castration-resistant prostate cancer: emerging strategies, challenges, and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Bo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShuLian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_200967","article-title":"Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment","volume":"38","author":"Hahn","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resistance Updates"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1621\/nrs.06008","article-title":"Diverse roles of androgen receptor (AR) domains in AR-mediated signaling","volume":"6","author":"Claessens","year":"2008","journal-title":"Nucl Recept Signal"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0085-0","article-title":"Alternative splicing in prostate cancer","volume":"15","author":"Paschalis","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3678","article-title":"Maintaining and reprogramming genomic androgen receptor activity in prostate cancer","volume":"14","author":"Mills","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1625","article-title":"Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition","volume":"27","author":"Annala","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.284","article-title":"Mechanisms of the androgen receptor splicing in prostate cancer cells","volume":"33","author":"Liu","year":"2014","journal-title":"Oncogene"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.12.039","article-title":"Pre-existing castration-resistant prostate cancer\u2013like cells in primary prostate cancer promote resistance to hormonal therapy","volume":"81","author":"Cheng","year":"2022","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100608","article-title":"Management of prostate cancer by targeting 3\u03b2HSD1 after enzalutamide and abiraterone treatment","volume":"3","author":"Mei","year":"2022","journal-title":"Cell Rep Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.5119","article-title":"randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5","volume":"33","author":"Fizazi","year":"2015","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1432","article-title":"Androgen receptor modulation optimized for response (ARMOR) phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer","volume":"22","author":"Montgomery","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.034","article-title":"Androgen receptor modulation optimized for response-splice variant: A phase 3, randomized trial of galeterone versus enzalutamide in androgen receptor splice variant-7-expressing metastatic castration-resistant prostate cancer","volume":"76","author":"Taplin","year":"2019","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1029-9","article-title":"Enzalutamide: A review in castration-resistant prostate cancer","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-12-2910","article-title":"Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer","volume":"19","author":"Hoffman-Censits","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30898-2","article-title":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial","volume":"20","author":"Tombal","year":"2019","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL trial","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101644","article-title":"HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES","volume":"5","author":"Sharifi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.006","article-title":"HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies","volume":"31","author":"Khalaf","year":"2020","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102152","article-title":"Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis","volume":"93","author":"Cassinello","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02394","article-title":"Randomized phase III study of enzalutamide compared with enzalutamide plus abiraterone for metastatic castration-resistant prostate cancer (Alliance A031201 trial)","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3402","article-title":"Pharmacokinetics, safety, and antitumor effect of apalutamide with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: phase Ib study","volume":"26","author":"Posadas","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0358","article-title":"Blood biomarker landscape in patients with high-risk nonmetastatic castration-resistant prostate cancer treated with apalutamide and androgen-deprivation therapy as they progress to metastatic disease","volume":"27","author":"Smith","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.009","article-title":"A randomized, open-label, cross-over phase 2 trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer: patient preference and cognitive function in ODENZA","volume":"85","author":"Colomba","year":"2024","journal-title":"Eur Urol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"Eur Urol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201859","article-title":"De novo design of an androgen receptor DNA binding domain-targeted peptide PROTAC for prostate cancer therapy","volume":"9","author":"Ma","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400398","article-title":"UBX-390: A novel androgen receptor degrader for therapeutic intervention in prostate cancer","volume":"11","author":"Lee","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7150\/thno.41849","article-title":"Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy","volume":"10","author":"Liao","year":"2020","journal-title":"Theranostics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.038","article-title":"PARP inhibitors for prostate cancer: tangled up in PROfound and PROpel (and TALAPRO-2) blues","volume":"84","author":"Beije","year":"2023","journal-title":"Eur Urol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1470-2045(22)00017-1","article-title":"Pain and health-related quality of life with olaparib versus physician\u2019s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial","volume":"23","author":"Thiery-Vuillemin","year":"2022","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102623","article-title":"Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials","volume":"120","author":"Iannantuono","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4103\/iju.iju_307_23","article-title":"Talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer: TALAPRO-2 trial","volume":"39","author":"Gupta","year":"2023","journal-title":"Indian J Urol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2023.05.017","article-title":"Are PARP inhibitors ready for prime time in metastatic prostate cancer? Maybe not","volume":"85","author":"Gonz\u00e1lez-Padilla","year":"2024","journal-title":"Eur Urol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02947","article-title":"Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer: the results from national cancer institute 9984","volume":"41","author":"Kim","year":"2023","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2526","article-title":"Phase I study of niraparib in combination with radium-223 for the treatment of metastatic castrate-resistant prostate cancer","volume":"29","author":"Quinn","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004761","article-title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","volume":"10","author":"Fizazi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.09.010","article-title":"Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib","volume":"83","author":"Loehr","year":"2023","journal-title":"Eur Urol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24200","article-title":"DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells","volume":"81","author":"Chao","year":"2021","journal-title":"Prostate"},{"key":"B62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2021.03.003","article-title":"Prostate cancer theranostics: from target description to imaging","volume":"16","author":"Alberts","year":"2021","journal-title":"PET Clin"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and Malignant human tissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J Surg"},{"key":"B65","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.7150\/thno.35759","article-title":"Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617","volume":"9","author":"Kessel","year":"2019","journal-title":"Theranostics"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00440-6","article-title":"Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/pros.23922","article-title":"PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and\/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study","volume":"80","author":"Petrylak","year":"2020","journal-title":"Prostate"},{"key":"B72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11912-015-0495-4","article-title":"Radionuclide therapies in prostate cancer: integrating radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer","volume":"18","author":"Nilsson","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"B73","article-title":"Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J Nucl Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0251-x","article-title":"Radium-223 mechanism of action: implications for use in treatment combinations","volume":"16","author":"Morris","year":"2019","journal-title":"Nat Rev Urol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.025","article-title":"A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer","volume":"31","author":"Sternberg","year":"2020","journal-title":"Ann Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70474-7","article-title":"Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.06.021","article-title":"Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial","volume":"73","author":"Parker","year":"2018","journal-title":"Eur Urol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13046-021-02056-9","article-title":"The role of dosimetry and biological effects in metastatic castration-resistant prostate cancer (mCRPC) patients treated with (223)Ra: first in human study","volume":"40","author":"Sciuto","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4476","article-title":"Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer","volume":"27","author":"Marshall","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0063","article-title":"A phase Ib study of atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer","volume":"27","author":"Fong","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","article-title":"Novel approaches to target the microenvironment of bone metastasis","volume":"18","author":"Hofbauer","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"B84","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-019-05271-5","article-title":"A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study","volume":"31","author":"Yoshida","year":"2020","journal-title":"Osteoporos Int"},{"key":"B88","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/cen.14169","article-title":"Hypocalcaemia following denosumab in prostate cancer: A clinical review","volume":"92","author":"Lau","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013020.pub2","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis","volume":"12","author":"Jakob","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3436","article-title":"A signal-finding study of abemaciclib in heavily pretreated patients with metastatic castration-resistant prostate cancer: results from CYCLONE 1","volume":"30","author":"Agarwal","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4302","article-title":"A phase Ib\/II study of the CDK4\/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer","volume":"28","author":"de Kouchkovsky","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Song","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"B97","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.20.01576","article-title":"Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: A randomized, placebo-controlled phase II trial (ProCAID)","volume":"39","author":"Crabb","year":"2021","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.05.019","article-title":"Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 proCAID clinical trial","volume":"82","author":"Crabb","year":"2022","journal-title":"Eur Urol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2326","article-title":"Phase Ib\/II study of enzalutamide with samotolisib (LY3023414) or placebo in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Sweeney","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00034-2","article-title":"Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study","volume":"25","author":"Layman","year":"2024","journal-title":"Lancet Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1115","article-title":"Open-label, dose-finding study of GSK2636771, a PI3K\u03b2 Inhibitor, administered with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"27","author":"Sarker","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41416-023-02487-5","article-title":"Phase 1b study of enzalutamide plus CC-115, a dual mTORC1\/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)","volume":"130","author":"Zhao","year":"2024","journal-title":"Br J Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.002","article-title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","volume":"31","author":"Ge","year":"2020","journal-title":"Ann Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","article-title":"Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","volume":"15","author":"Venkadakrishnan","year":"2024","journal-title":"Nat Commun"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac861","article-title":"A cryptic transactivation domain of EZH2 binds AR and AR\u2019s splice variant, promoting oncogene activation and tumorous transformation","volume":"50","author":"Wang","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br J Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2828","article-title":"HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4\/6 inhibitor resistance in cancer","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1078-0432.CCR-18-1589","article-title":"Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer","volume":"25","author":"Ferrari","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0175","article-title":"Phase Ib study of the BET inhibitor GS-5829 as monotherapy and combined with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Aggarwal","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A phase Ib\/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102057","article-title":"Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes","volume":"88","author":"Claps","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz3577","article-title":"Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer","volume":"12","author":"Subudhi","year":"2020","journal-title":"Sci Trans Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02915-6","article-title":"Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer","volume":"70","author":"Witt","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.11.034","article-title":"Efficacy and safety of programmed death-1 (PD-1)\/programmed death-ligand 1 (PD-L1) checkpoint inhibitors in patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis","volume":"36","author":"Hong","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1133","article-title":"KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer","volume":"17","author":"Petrylak","year":"2021","journal-title":"Future Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00865-5","article-title":"Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study","volume":"28","author":"Graff","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.10.008","article-title":"Pembrolizumab and enzalutamide in patients with abiraterone acetate\u2013pretreated metastatic castration-resistant prostate cancer: cohort C of the phase 1b\/2 KEYNOTE-365 study","volume":"7","author":"Yu","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100613","article-title":"Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer","volume":"3","author":"Siddiqui","year":"2022","journal-title":"Cell Rep Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-3403","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12967-022-03827-4","article-title":"Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer","volume":"21","author":"Han","year":"2023","journal-title":"J Transl Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/cells11010020","article-title":"Myeloid-derived suppressor cells in prostate cancer: present knowledge and future perspectives","volume":"11","author":"Koinis","year":"2021","journal-title":"Cells"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff Philip","year":"2010","journal-title":"New Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-20-0252","article-title":"Long-term sculpting of the B-cell repertoire following cancer immunotherapy in patients treated with sipuleucel-T","volume":"8","author":"Zhang","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-0638","article-title":"Antigen-specific CD8 lytic phenotype induced by sipuleucel-T in hormone-sensitive or castration-resistant prostate cancer and association with overall survival","volume":"24","author":"Antonarakis","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B134","year":""},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.2_suppl.165","article-title":"Sipuleucel-T (sip-T)\u2013induced proliferative CD8+ T-cell responses to immunizing and secondary antigens","volume":"34","author":"Antonarakis","year":"2010","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002903","article-title":"IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Pachynski","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002254","article-title":"Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"Sinha","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.120","article-title":"Development of PROSTVAC immunotherapy in prostate cancer","volume":"11","author":"Singh","year":"2015","journal-title":"Future Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902997928","article-title":"Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer","volume":"18","author":"Madan","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"B141","article-title":"Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects","volume":"61","author":"Grosenbach","year":"2001","journal-title":"Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10130","article-title":"Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer","volume":"53","author":"Gulley","year":"2002","journal-title":"Prostate"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.04.013","article-title":"Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial)","volume":"78","author":"Merino","year":"2018","journal-title":"Hum Pathol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0108","article-title":"Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer","volume":"2","author":"Gulley","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0782-8","article-title":"Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer","volume":"59","author":"Gulley","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B147","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/oncolo\/oyad058","article-title":"Flutamide with or without PROSTVAC in non-metastatic castration resistant (M0) prostate cancer","volume":"28","author":"Madan","year":"2023","journal-title":"Oncologist"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.5173\/ceju.2021.0094","article-title":"Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology","volume":"74","author":"Lasek","year":"2021","journal-title":"Cent Eur J Urol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23669","article-title":"Phase 1\/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer","volume":"113","author":"Higano","year":"2008","journal-title":"Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2005.08.021","article-title":"Granulocyte-macrophage colony-stimulating factor\u2013transduced allogeneic cancer cellular immunotherapy: The GVAX\u00ae vaccine for prostate cancer","volume":"24","author":"Simons","year":"2006","journal-title":"Urologic Oncol Semin Original Investigations"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2299","article-title":"Immunotherapy for prostate cancer: walk, don\u2019t run","volume":"27","author":"Drake","year":"2009","journal-title":"J Clin Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13025","article-title":"Peptide-based therapeutic cancer vaccine: Current trends in clinical application","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104643","article-title":"Key considerations for a prostate cancer mRNA vaccine","volume":"208","author":"Lin","year":"2025","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02498-8","article-title":"Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial","volume":"69","author":"Noguchi","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7847","article-title":"A randomized phase III trial of personalized peptide vaccination for castration\u2212resistant prostate cancer progressing after docetaxel","volume":"45","author":"Noguchi","year":"2021","journal-title":"Oncol Rep"},{"key":"B156","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.eururo.2015.12.050","article-title":"A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer","volume":"70","author":"Yoshimura","year":"2016","journal-title":"Eur Urol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124519","article-title":"DNA aptamer-conjugated lipid nanoparticle for targeted PTEN mRNA delivery to prostate cancer cells","volume":"662","author":"Sam Lee","year":"2024","journal-title":"Int J Pharmaceutics"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-0945","article-title":"Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer","volume":"26","author":"Kyriakopoulos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008067","article-title":"Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer","volume":"11","author":"McNeel","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01701","article-title":"Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP [MVI-816]) in patients with progressive, nonmetastatic, castration-sensitive prostate cancer","volume":"37","author":"McNeel","year":"2019","journal-title":"J Clin Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002374","article-title":"Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Bilusic","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03024-0","article-title":"Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial","volume":"70","author":"Filaci","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac048","article-title":"ADXS31142 immunotherapy \u00b1 Pembrolizumab treatment for metastatic castration-resistant prostate cancer: open-label phase I\/II KEYNOTE-046 study","volume":"27","author":"Stein","year":"2022","journal-title":"Oncologist"},{"key":"B164","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104604","article-title":"Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management","volume":"207","author":"Chen","year":"2025","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01742-1","article-title":"CAR T cells reach clinical milestone in prostate cancer","volume":"28","author":"Tschernia","year":"2022","journal-title":"Nat Med"},{"key":"B168","doi-asserted-by":"publisher","first-page":"10743","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat Commun"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"key":"B170","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s40425-019-0741-7","article-title":"CAR-T cell therapy: a potential new strategy against prostate cancer","volume":"7","author":"Schepisi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B171","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12967-019-02206-w","article-title":"IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model","volume":"18","author":"Wang","year":"2020","journal-title":"J Trans Med"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1358\/dof.2008.033.02.1172578","article-title":"BiTE: a new class of antibodies that recruit T-cells","volume":"33","author":"Baeuerle","year":"2008","journal-title":"Drugs Future"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24826","article-title":"Personalized medicine: leave no patient behind; report from the 2024 coffey-holden prostate cancer academy meeting","volume":"85","author":"Miyahira","year":"2025","journal-title":"Prostate"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2356820","article-title":"T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer","volume":"25","author":"Palecki","year":"2024","journal-title":"Cancer Biol Ther"},{"key":"B175","doi-asserted-by":"publisher","first-page":"e11902","DOI":"10.15252\/emmm.201911902","article-title":"An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer","volume":"13","author":"Zekri","year":"2021","journal-title":"EMBO Mol Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-1483","article-title":"Novel redirected T-cell immunotherapies for advanced prostate cancer","volume":"28","author":"Dorff","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-2005","article-title":"Human T cells armed with Her2\/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation","volume":"12","author":"Grabert","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-1601","article-title":"Phase II trial of pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer","volume":"29","author":"Vaishampayan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B180","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012647","article-title":"Oncolyic virotherapy for prostate cancer: lighting a fire in winter","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.151","article-title":"Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice","volume":"117","author":"Martikainen","year":"2017","journal-title":"Br J Cancer"},{"key":"B183","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41417-021-00360-2","article-title":"Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models","volume":"29","author":"van de Merbel","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.7150\/jca.46868","article-title":"Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer","volume":"12","author":"Mao","year":"2021","journal-title":"J Cancer"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005007","article-title":"Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors","volume":"11","author":"Rudin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B188","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12321","article-title":"The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death","volume":"42","author":"Wu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B190","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin Transl Med"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.S466396","article-title":"Synergistic potential of nanomedicine in prostate cancer immunotherapy: breakthroughs and prospects","volume":"19","author":"Jiang","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"B192","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann Oncol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605599","article-title":"Epidemiology and pathophysiology of cancer-associated thrombosis","volume":"102","author":"Noble","year":"2010","journal-title":"Br J Cancer"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006293422604","article-title":"Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism","volume":"342","author":"Schulman","year":"2000","journal-title":"New Engl J Med"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.ccell.2024.08.018","article-title":"Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer","volume":"42","author":"Cal\u00ec","year":"2024","journal-title":"Cancer Cell"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1148021","article-title":"Combination therapy for high-volume versus low-volume metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis","volume":"14","author":"Jian","year":"2023","journal-title":"Front Pharmacol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"OP-25","DOI":"10.1200\/op-25-00050","article-title":"Prostate cancer foundation white paper on combination therapy for metastatic hormone-sensitive prostate cancer","author":"Carlsson","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"B198","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","article-title":"Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: A systematic review","volume":"87","author":"Francini","year":"2025","journal-title":"Eur Urol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316607","article-title":"Genetic testing enhances the precision diagnosis and treatment of breast cancer","volume":"24","author":"Yang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.162","article-title":"Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED","volume":"38","author":"Hamid","year":"2020","journal-title":"J Clin Oncol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Ann Oncol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02234-9","article-title":"Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer","volume":"24","author":"Pan","year":"2025","journal-title":"Mol Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1668188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:06Z","timestamp":1761111126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1668188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":203,"alternative-id":["10.3389\/fimmu.2025.1668188"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1668188","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1668188"}}